產(chǎn)品名稱

Gefitinib - ZD 1839 | Iressa

產(chǎn)品貨號(hào)

Axon 1393 CAS [184475-35-2] MF C22H24ClFN4O3MW 446.90 Purity: 99% Soluble in DMSO Description Selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor References Certificates Categories Extra info G Blackledge, S Averbuch. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br. J. Cancer 2004, 90(3), 566-72. ? JG Paez et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676), 1497-500. Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology EGFR JAK-STAT RTK class I; EC 2.7.10.1 EGFR tyrosine kinase inhibitor Chemical name N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine Parent CAS No. [184475-35-2] Order Size Unit Price Stock 10 mg €70.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

Gefitinib - ZD 1839 | Iressa

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 1393

CAS [184475-35-2]

MF C22H24ClFN4O3
MW 446.90

Purity: 99%
Soluble in DMSO

Gefitinib

Description

Selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor

G Blackledge, S Averbuch. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br. J. Cancer 2004, 90(3), 566-72.

JG Paez et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676), 1497-500.

Certificate of Analysis
Material Safety Data Sheet

Angiogenesis Cell Signaling & Oncology EGFR JAK-STAT RTK class I; EC 2.7.10.1

EGFR tyrosine kinase inhibitor

Chemical name

N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine

Parent CAS No.

[184475-35-2]

產(chǎn)品資料